Andrew Callos Sells 8,659 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 8,659 shares of the stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $32.04, for a total value of $277,434.36. Following the completion of the transaction, the executive vice president now owns 52,028 shares in the company, valued at approximately $1,666,977.12. The trade was a 14.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Andrew Callos also recently made the following trade(s):

• On Monday, May 5th, Andrew Callos sold 4,002 shares of Cytokinetics stock. The stock was sold at an average price of $36.68, for a total transaction of $146,793.36.
• On Monday, April 7th, Andrew Callos sold 2,886 shares of Cytokinetics stock. The shares were sold at an average price of $35.78, for a total value of $103,261.08.
• On Monday, March 17th, Andrew Callos sold 2,775 shares of Cytokinetics stock. The stock was sold at an average price of $44.38, for a total transaction of $123,154.50.
• On Friday, March 14th, Andrew Callos sold 100 shares of Cytokinetics stock. The stock was sold at an average price of $45.00, for a total value of $4,500.00.

Cytokinetics Stock Up 1.8%

NASDAQ CYTK traded up $0.58 during trading on Friday, reaching $32.66. 312,702 shares of the company's stock were exchanged, compared to its average volume of 1,562,122. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. Cytokinetics, Incorporated has a 1 year low of $29.31 and a 1 year high of $61.38. The company has a 50 day moving average price of $35.34 and a two-hundred day moving average price of $43.08. The stock has a market cap of $3.90 billion, a P/E ratio of -6.06 and a beta of 0.59.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) earnings per share for the quarter, beating analysts' consensus estimates of ($1.41) by $0.05. The firm had revenue of $1.60 million during the quarter, compared to analysts' expectations of $2.77 million. The business's quarterly revenue was up 89.1% on a year-over-year basis. During the same quarter last year, the business earned ($1.33) earnings per share. On average, equities research analysts anticipate that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CYTK. Jones Financial Companies Lllp increased its stake in Cytokinetics by 189.8% during the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 374 shares during the last quarter. Centricity Wealth Management LLC acquired a new position in Cytokinetics during the fourth quarter valued at approximately $29,000. Fifth Third Bancorp raised its stake in shares of Cytokinetics by 42.2% in the 1st quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 291 shares during the period. Parallel Advisors LLC lifted its holdings in shares of Cytokinetics by 500.5% during the 1st quarter. Parallel Advisors LLC now owns 1,099 shares of the biopharmaceutical company's stock valued at $44,000 after acquiring an additional 916 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in Cytokinetics by 281.0% during the 1st quarter. GAMMA Investing LLC now owns 1,120 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 826 shares during the period.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on CYTK shares. Royal Bank of Canada lowered their price target on shares of Cytokinetics from $82.00 to $80.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Citigroup lowered their price objective on Cytokinetics from $86.00 to $80.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Cantor Fitzgerald raised shares of Cytokinetics to a "strong-buy" rating in a research note on Tuesday, May 13th. Evercore ISI upgraded Cytokinetics to a "strong-buy" rating in a report on Friday, February 7th. Finally, Barclays dropped their price objective on shares of Cytokinetics from $55.00 to $53.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $72.31.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.